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[72_TD$DIFF]A B S T R A C T
The aim of the present study was to create an optimal workﬂow for analysing a large cohort of malignant
melanoma tissue samples. Samples were lysed with urea and enzymatically digested with trypsin or
trypsin/Lys C. Buffer exchange or dilution was used to reduce urea concentration prior to digestion. The
tissue digests were analysed directly or following strong cation exchange (SCX) fractionation by nano
LC–MS/MS. The approach which resulted in the largest number of protein IDs involved a buffer exchange
step before enzymatic digestion with trypsin and chromatographic separation in 120min gradient
followed by SCX–RP separation of peptides.
ã 2015 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Malignant melanoma is deﬁned as cancer of melanocytes, the
cells that produce pigment, melanin, in the skin [1]. Metastatic
malignant melanoma is a complex disease with unfavorable
prognosis and has one of the highest incidence rates globally.
According to World Health Organization statistics report, a
perceptible increase in melanoma cancer incidents has been
observed during the last decade with Scandinavian countries, The
Netherlands, Switzerland and Slovenia showing the highest
number of cases reported [2]. The 5-year survival rate inmetastatic
melanoma is around 5% and the median survival is only 6–10
months [3,4]. At the time of diagnosis 10–15% of the patients are
diagnosed with disseminated disease and hence have a poor
prognosis. To this date there is no effective cure for malignant
melanoma when the [70_TD$DIFF]tumour has spread to multiple organs
because of its extraordinary resistance to apoptosis [5]. As a result,
melanoma is resistant to classical chemotherapy, radiotherapy and
immunotherapy [1].
Currently there are no blood or tissue biomarkers available
for early detection, identifying disease progression or monitoring
response for the treatment of malignant melanoma. A number of
markers associated with malignant melanoma (e.g S-100 and
5-S-cysteinyldopa) are under investigation, but their relevance
to melanoma progression, clinical outcome and the selection of
optimal treatment strategies still needs to be established [6,7].
The most common treatment of the early-diagnosed malignant
melanoma patients includes surgical resection which cures most
patients. For treatment of patients who developed distant
metastases, administration of drugs, targeting immune response
(Ipilimumab) or tyrosine kinases (Verumafenib) as well as
adjuvant therapy with recombinant interleukin 2 (IL-2) is used.
Although a few months increase in a lifetime can be accom-
plished by use of any speciﬁc drug or combination of drugs, a
little or no effect on median survival of patients is usually
observed [1,4]. The reason behind bleak survival prognosis lies in
poor understanding of the mechanisms underlying disease
development and lack of knowledge about the mechanisms of
drug resistance.
Gene expression signatures of melanoma cancer have been
proposed to classifymelanoma patients into distinct subtypeswith
differential clinical outcomes [8–12]. Winnepenninckx et al.
identiﬁed a 254 gene expression signature associated with a
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4-year distant metastasis-free survival when analysing 58 primary
cutaneous melanomas [10]. Recently four subtypes of melanoma
cancer characterised by different gene proﬁles (‘proliferative’,
‘high-immune response’, ‘pigmentation’ and ‘normal-like’) were
proposed and these groups were signiﬁcantly linked to patient
survival [8]. Although gene signatures could provide valuable
information, cell [73_TD$DIFF]behaviour is mainly determined by ﬁnal structure
and availability of proteins. Therefore, analysing changes in protein
expression levels may be better suited for understanding the
mechanisms underlying melanoma progression [13].
Mass spectrometry has become a powerful tool for unambig-
uous identiﬁcation and quantiﬁcation of proteins in complex
biological samples [14]. Abundance of proteins has great
biological signiﬁcance and determination of protein expression
levels, their post-translational modiﬁcations and their interac-
tions in association with disease processes is therefore impor-
tant. Several MS-based proteomics methods have emerged in
recent years including shotgun approach – universal for
discovery purposes. In a shotgun approach, proteins are
enzymatically digested into peptides, which are separated using
liquid chromatography (LC) and [74_TD$DIFF]analysed with tandem mass
spectrometry. Peptides are identiﬁed and correlated with the
corresponding proteins by matching generated tandem (MS/MS)
spectra with theoretical spectra in a protein sequence database
[14,15].
Even with advanced instrumentation, the number of proteins
identiﬁed with a conventional one-dimentional LC–MS/MS setup
is limited by the general complexity of sample proteome [16–18].
The difﬁculties when analysing complex biological samples with
shotgun approach led to the development of multidimensional
analysis of protein identiﬁcation technology (MudPIT) pioneered
by Yates and colleagues [19–22]. The technique is based on two-
dimensional chromatographic separation of peptides by charge
(SCX) and hydrophobicity (RP) followed by tandem MS analysis.
MudPIT can be performed in online or ofﬂine mode with each
approach having its beneﬁts and drawbacks [23].
The present study focuses on deﬁning the methodology for
large-scale analysis of melanoma tissue samples resulting in the
largest number of identiﬁed proteins. The power of the ofﬂine
separation (SCX fractionation) for acquiring deep proteome data
in shotgun analysis is demonstrated. Two different strategies for
sample cleanup before enzymatic digestion are compared and
the value of replicated sample injections is explored. A
combination of [75_TD$DIFF]optimised workﬂow and state-of-art instru-
mentation: nanoLC coupled to hybrid quadrupole–Orbitrap
mass spectrometer, opens up the possibility for controlled
analysis of large sample cohorts and increases the number of
identiﬁcations within single LC–MS run. Protein expression level
data will be collected in a local melanoma database and used to
deepen knowledge about various disease subtypes and drug
resistance.
2. Materials and methods
2.1. Reagents and solutions
All chemical reagents were purchased from Sigma Aldrich (St.
Lois, MO) unless otherwise speciﬁed. Water and organic solvents
were of LC–MS quality and supplied by Merck (Darmstadt,
Germany). All solutions were degased by sonication before use.
2.2. Tissue samples and sample preparation
Ten lymph node metastasis samples (Stage III) from patients
with malignant melanoma, archived in the local malignant
melanoma biobank were obtained from Skåne University Hospital,
Sweden. Each sample was marked as ‘MM’ followed by identiﬁca-
tion number. Ethical approval was granted by Central Ethical
Reviewboard at LundUniversity; approval number:DNR 191/2007,
101/2013. All patients within the study provided a written
informed consent. The malignant melanoma biobank “Tissuebank
for research on [70_TD$DIFF]tumour diseases” (BD20)” is located at Barngatan
2B, 221 85 Lund, Sweden. Frozen tissue samples from BD20 were
sectioned on a cryostat into 10mm thick slices (approximately
6 6mm), placed into a 96 well plate and stored at 80 C until
further use. From each tissue 5 slices were withdrawn for sample
preparation. Patient characteristics are summarised in Table 1.
2.3. Tissue lysis and protein extraction
Frozen tissue slices were lysed with 6M urea in 50mM
ammonium bicarbonate buffer (50mM AmBic) for 30min with
constant shaking (500 rpm) on ice. Samples were additionally
vortexed for 10min in order to promote protein extraction. After
incubation with urea the lysate was sonicated for 5min and
centrifuged at room temperature on a benchtop Eppendorf
centrifuge 5415 R (10,000g, 10min, Eppendorf Nordic Aps,
Horsholm, Denmark). Supernatant was transferred into a new
tube and the pellet was discarded. Protein concentration was
measured using a bicinchoninic acid protein assay according to the
manufacturer’s instructions (Micro BCA kit, Pierce/Thermo Scien-
tiﬁc, Rockford, IL). Brieﬂy, stock solution of BSA (2mgmL1) was
diluted with Milli-Q water to the following concentrations: 0;
0.005; 0.0075; 0.01; 0.015 and 0.02mgmL1 for construction of the
calibration curve. Hundredmicroliter of diluted sample and 100mL
of each calibration solution were mixed with equal volume of
working BCA reagent (containing 50:48:2 parts of reagent A, B and
C, respectively) in a 96-well plate. [76_TD$DIFF]Colour development was
allowed to take place at 60 C for 30min. Absorbance was
measured with FLUOstar Omega (BMG LABTECH, Ortenberg,
Germany) at 562nm. Protein and peptide concentrations
were calculated from an equation of the calibration curve
using dilution factor. Tissue lysate containing 100mg of total
Table 1
Patient and [70_TD$DIFF]tumour characteristics. Breslow [70_TD$DIFF]tumour thickness (T class) and Clarks level of invasion refer to the primary melanoma.
Sample ID Gender Age at primary melanoma Years from primary diagnosis to diagnosed metastasis Breslow class Clark level Status
MM35 Male 54 1 3 4 Alive
MM98 Male 73 2 4 4 Dead
MM504 Male NA Dead
MM687 Male 72 2 1 2 Dead
MM787 Male 78 [71_TD$DIFF]3 2 4 Dead
MM812 Male NA Alive
MM813 Female 54 0 2 3 Alive
MM825 Female 64 2 2 4 Alive
MM829 Male 49 6 1 2 Alive
MM835 Female 32 4 3 3 Alive
NA – not available, primary [70_TD$DIFF]tumour not diagnosed.
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proteinwas used for sample preparation. The samples were spiked
with 0.1mg of internal standard – chicken lysozyme (CL, Swiss-Prot
accession no. P00698).
2.4. In-solution digestion with trypsin or trypsin/Lys C
Two different approaches were used for sample preparation
before a digestion step. The ﬁrst approach employed dilution of the
tissue lysate with 50mM AmBic to achieve 1M or 3M urea
concentration (workﬂow 2). In the second approach (workﬂow 1)
urea was removed from the samples using Amicon Ultra
centrifugal ﬁlter (0.5mL – 10kDa, Millipore, Ireland) according
to themanufacturer’s instructions. Samples resuspended in 50mM
AmBic were used for enzymatic proteolysis.
Prior to digestion the protein’s disulﬁde bonds were reduced by
10mM dithiothreitol (DTT) for 1h at 37 C and alkylated with
50mM iodoacetamide (IAA) for 30min at room temperature [77_TD$DIFF]in a
darkness. Trypsin (Promega, Madison, WI) was added to the
samples in a ratio of 1:100 (w/w) and digestionwas performed in a
thermoblock (ThermoMixer comfort, Eppendorf Nordic Aps,
Horsholm, Denmark) at 37 C with constant shaking (600 rpm).
After 18h of incubation proteolysis was terminated by addition of
10% formic acid to a ﬁnal concentration of 0.1%. Sampleswere dried
using a centrifugal evaporator and resuspended in water contain-
ing 0.1% formic acid. Prior to injection onto LC–MS/MS the samples
weremixedwith peptide retention time calibrationmixture (PRTC,
Pierce/Thermo Scientiﬁc, Rockford, IL, 25 fmoLmL1).
A mixture of trypsin/Lys C was directly added to tissue lysates
containing 6M urea in a ratio of 1:25 (w/w). After 4h of incubation
the lysates were diluted to obtain ﬁnal concentrations of 1M and
3M urea, and proteolysis was allowed to take place for another
14h. Other steps in the protocol were the same as described for
trypsin digestion.
2.5. Fractionation
Strong cation exchange (SCX) chromatography was performed
using Microspin columns (MA SEM HIL-SCX, 10–100mg capacity,
The Nest group Inc., South Borough) according to the manufac-
turer’s instruction. Stepwise gradient of potassium chloride: 20,
40, 60, 100, 500mM and 1M KCl in 10mM potassium phosphate
containing 20% acetonitrile, pH 2.8 was used for fractionation of
peptides. The fractionated samples were dried using a centrifugal
evaporator and resuspended in 0.1% triﬂuoroacetic acid (TFA). Salt
was removed from the samples by Ultra Microspin column Silica
C18 (SUM SS18V, 3–30mg capacity, The Nest group Inc., South
Borough) following the instruction recommended by the manu-
facturer. After elution with 50% acetonitrile/0.1% TFA, the fractions
were dried using a centrifugal evaporator and resuspended in 0.1%
formic acid. Prior to injection onto LC–MS/MS the samples were
mixed with PRTC (25 fmoLmL1).
2.6. Chromatographic separation
The peptides produced by digestion were ﬁrst loaded onto a
trap column (Acclaim1 PepMap 100 pre-column, 75mm2 cm,
C18, 3mm, 100Å, Thermo Scientiﬁc, San José, CA) and then
separated on an analytical column (EASY-Spray column, 50 cm
75mm ID, PepMap RSLC C18, 2mm,100Å, Thermo Scientiﬁc, San
José, CA). Flow rate of 300nLmin1 and a column temperature of
35 Cwere [78_TD$DIFF]utilised. A nonlinear gradientwas applied, using solvent
A (0.1% formic acid) and solvent B (0.1% formic acid in acetonitrile).
The gradient went from 5% to 40% B in the ﬁrst 120min, followed
by raise to 90% B in the next 5min, which was maintained for
10min. The total protein amount of unfractionated [70_TD$DIFF]tumour digest
injected onto the column was 2mg and for the fractionated
samples the protein amount was estimated to be 1mg (50mg of
peptides were fractionated into 6 fractions, approx. 8.3mg in each
fraction). Unfractionated samples were injected in random order,
while fractionated samples were injected in the order of increasing
salt concentration used for elution of the peptides. To avoid
carryover each sample injection followed by a blank injection
(water containing 0.1% formic acid).
2.7. Mass spectrometry acquisition method
Both unfractionated and fractionated [79_TD$DIFF]tumour digests were
analysed using a Q-Exactive Plus mass spectrometer connected to
an Easy-nLC 1000 pump (Thermo Scientiﬁc, San José, CA) with a
top 10 data-dependent acquisition (DDA) method. Full MS scans
were acquired with the Orbitrap mass analyser overm/z 350–1800
range with resolution of 70,000 (at m/z 200), target AGC value of
1e6 and maximum injection time of 100ms. The ten most intense
peaks with charge state 2 were fragmented in the HCD collision
cell with [80_TD$DIFF]normalised collision energy of 30%, and tandem mass
spectra were acquired in the Orbitrap mass analyzer with
resolution of 35,000 (at m/z 200), target AGC value of 1e6 and
maximum injection time of 120ms. The ion selection threshold
was set to 4.2e4 and dynamic exclusion was 20 s.
2.8. Data analysis
Raw ﬁles were [74_TD$DIFF]analysed with Proteome Discoverer v 1.4
(Thermo Scientiﬁc, San José, CA). Peptides were identiﬁed using
SEQUEST HT against UniProtKB human database integrated into
Proteome Discoverer (release 2015_03, 42060 sequences including
isoforms) and using Mascot against UniProtKB human database
(release 2014_02, 20508 sequences, http://www.uniprot.org/
downloads). The search was performed with the following
parameters applied: carbamidomethylation as static modiﬁcation,
oxidation of methionine as dynamic modiﬁcation, 10ppm precur-
sor tolerance and 0.02Da fragment tolerance. Up to one missed
cleavage for tryptic peptides was allowed. Filters: ‘high conﬁdence’
and ‘at least two peptides per protein’ were applied (FDR0.01).
[81_TD$DIFF] he dataset associated with the current article is publicly
available in ProteomeXchange (http://www.proteomexchange.
org/): PXD002485 (unfractionated samples), PXD002487 (fraction-
ated samples).
3. Results and discussion
3.1. Comparison of various puriﬁcation strategies
A number of reagents used for proteomics sample preparation
are not compatible with endoproteinases and/or mass spectrome-
try. Therefore, the puriﬁcation step is an essential component of
sample preparation process. Different methodologies have been
developed in order to [82_TD$DIFF]minimise handling and improve sample
recovery for deep proteome analysis [24–26]. In a pilot study
reported byWelinder et al. [27] tissue lysates [83_TD$DIFF]solubilised with urea
were puriﬁed using a principle of diaﬁltration (buffer exchange,
workﬂow 1). Lowmolecular-weight compounds such as ureawere
separated from the high molecular-weight proteins using a semi-
permeable membrane. Concentrated proteins were collected by
centrifugation of the reversed membrane and redissolved in a
trypsin- and MS-compatible buffer solution. As demonstrated
before, increased sample handling results in subsequent loss of
material and decreased number of proteins, which can be
identiﬁed in a particular biological system [24]. To enable deeper
analysis of the complex tissue samples, buffer exchange was
comparedwith another approach in the present study. Tissue slices
(sample MM504) were ﬁrst lysed with 6M urea in 50mM AmBic.
80 M.E. Yakovleva et al. / EuPA Open Proteomics 8 (2015) 78–84
The obtained mixture of proteins was then diluted to achieve 3M
urea – concentration at which trypsin remains active (according to
manufacturer’s instructions). After enzymatic digestion, peptides
were desalted with C18 spin columns before LC–MS/MS analysis
(workﬂow 2). Output data for the two workﬂows was [74_TD$DIFF]analysed
with the aid of protein/peptides concentration determination and
the number of protein/peptide IDs.
Since a puriﬁcation step is inevitable for sample preparation,
loss of material would be expected for both preparation strategies.
The aim of the study was to select the methodology, which will
result inminor losses during sample preparation.Material loss was
estimated for both of the sample preparationworkﬂows using BCA
kit and tissue lysate MM504. Known amounts of tissue lysate
MM504 (0.3mgmL1) were digested using workﬂow 1 and
workﬂow 2. For workﬂow 1 the concentration of stock solution
was comparedwith the concentration of the same solution, passed
through Amicon ﬁlter (buffer exchange). For workﬂow 2 the
concentration of the stock solution was compared with the
concentration of the peptide mixture obtained after digestion
(Table 2).
For the buffer exchange, sample loss on a protein level was
observed (61% of original value, Table 2). For desalted samples
diluted prior to enzymatic digestion, sample loss on a peptide level
was observed (35% loss, Table 2). The number of identiﬁed
proteins/peptides for the two workﬂows was further [74_TD$DIFF]analysed.
Sample prepared using dilution to 3M urea in combination with
C18 puriﬁcation step provides fewer IDs compared with sample
where urea is removed by ultraﬁltration. Results presented in Fig.1
suggest that trypsin is not fully active at 3M urea. The number of
protein IDs is much lower for diluted tissue lysate in comparison
with the same sample puriﬁed by buffer exchange. The experiment
was repeated with urea diluted to 1M and results are shown in the
same ﬁgure (Fig. 1). As can be seen from Fig. 1, the highest number
of protein IDs was obtained for tissue lysate, which was puriﬁed by
diaﬁltration and redissolved in 50mM AmBic. A total of 2395
proteins, corresponding to 1361 protein groups and 10,251
peptides were identiﬁed using Proteome Discoverer in MM504
tissue sample lysate.
3.2. [84_TD$DIFF]Standardisation of bottom-up proteomics approach
To monitor the sample preparation process, chromatographic
separation and mass spectrometric measurements, two unintru-
sive standards were introduced. Chicken lysozyme (CL) was used
as an internal standard. The CL was added to each of the tissue
lysates prior to enzymatic digestion. A 1:1000 ratio of CL:protein
(w/w) was used throughout all the experiments [28]. Not all of the
CL tryptic peptides were identiﬁed in each run due to the
complexity of the matrix and the peculiar way precursors are
selected for MS/MS fragmentation. The digestion was considered
successful if the following six peptides were observed (NLCNIPC-
SALLSSDITASVNCAK, NTDGSTDYGILQINSR, IVSDGNGMNAW-
VAWR, FESNFNTQATNR, GYSLGNWVCAAK, GTDVQAWIR) and not
more than 1 miss-cleaved peptide was found [28].
Another standard used to evaluate the LC–MS/MS performance
was PRTC. It was added to each sample right before injection onto
the LC column. The amount of PRTC, needed for each injection, was
set to 50 fmoL per injection. This was the minimal amount of
internal standard, needed for detection of most of the heavy
labelled peptides (12–13 out of 15). The observed chromatographic
elution of heavy labelled peptides spiked intoMM504 tissue digest
as well as CL peptides was in a good correlation (r= 0.9903) with
the theoretical retention times calculated using an algorithm for
peptide retention prediction (SSRCalc 3.0), integrated into Skyline
[29]. Monitoring the RT variation of heavy labelled peptides spiked
into each tissue digest can serve as a good indicator for
chromatographic performance of the system.
3.3. Comparison of one and two enzyme digestion protocols
Since no additional protein identiﬁcations were gained by
diluting tissue lysates to 1M urea, two digestion protocols were
compared, trypsin alone and trypsin plus Lys C. Lys C/trypsin is a
commercially available mixture for two step digestion, developed
by McDonald et al. [20]. Application of the two enzyme approach
improves proteolytic efﬁciency and reduces the number of miss-
cleaved peptides. Lys C is active at high concentrations of
denaturing agents and it is able to cleave relatively large proteins
to smaller fragments, which becomemore accessible for trypsin at
lower urea concentrations. The comparison of one and two enzyme
digestion protocolswas performed using theMM835 tissue sample
prepared according to two workﬂows: buffer exchange and
dilution to 1M urea (Fig. 2).
The number of protein IDs for tissue samples digested by
trypsin alone was similar to the number obtained with the
combination of two enzymes. Notably, data obtained from
digestion with one enzyme only had a better quality than two
enzymes data. Tryptic digestionprovided slightly higher number of
unique peptides and better sequence coverage for identiﬁed
proteins than peptides obtained with trypsin/Lys C. Perhaps, the
protein to enzyme ratio recommended by the manufacturer is not
suitable for the type of material used in our study and should be
Table 2
Comparison of puriﬁcation techniques using BCA assay and tissue lysate MM504.
Equation of BSA calibration curve Concentration of MM504 peptide digest after diaﬁltration
(mgmL1)
Concentration of MM504 peptide digest after dilution, (mgmL1)
y = 0.0413x + 0.0769 (R2 = 0.9756) 0.220.0039 0.370.0065
[(Fig._1)TD$FIG]
Fig. 1. The number of identiﬁed protein groups in MM504 tissue digests prepared
by buffer exchange or dilution to 3M urea or 1M urea prior to enzymatic digestion
with trypsin and measured in duplicate. Peptides were separated on a 50 cm long
column (75mm2mm) in a 90min gradient at a ﬂow rate of 300nLmin1. Protein
IDs were obtained by joined SEQUEST HT/Mascot search in Proteome Discoverer.
Filters applied in Proteome Discoverer: high peptide conﬁdence and at least 2
peptides per protein.
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further optimised for increasing the number of protein identi-
ﬁcations, which can be identiﬁed in a single LC–MS/MS run. From
the practical point of view, digestionwith trypsin alone seems less
laborious and provides better quality data.
3.4. Optimisation of the gradient length
A pronounced increase in the number of identiﬁed peptides and
corresponding proteins for deep proteome analysis can be
obtained by increasing the length of the column and gradient
length as demonstrated in a number of recent articles [30,31]. In
the present study, MM835 tissue samples were prepared using
workﬂows employing either buffer exchange or dilution to 1M
urea before enzymatic digestion with one or two enzymes. Then
the number of identiﬁed peptides/proteins was compared for 90
and 120min gradients.
The [85_TD$DIFF]summarised results are presented in Fig. 3. The total
number of identiﬁed proteins was higher when peptides were
separated in 2h gradient for all of the sample preparation
protocols. In the buffer exchanged tissue samples, 381 and 373
additional proteins were detected (for trypsin and trypsin/Lys C
digestion protocols, respectively). The samples diluted to 1M urea
concentration provided 312 and 318 new protein IDs with a longer
gradient time (for trypsin and trypsin/Lys C digestion protocols,
[(Fig._2)TD$FIG]
Fig. 2. The number of protein groups identiﬁcations with the top 10 method for melanomaMM835 tissue lysates prepared by (1) buffer exchange or (2) dilution to 1M urea
prior to enzymatic digestionwith trypsin or trypsin/Lys C. Samples were analysed in duplicate. Peptides were separated on a 50 cm long column (75mm2mm) in a 90min
(A) or 120min (B) gradient at a ﬂow rate of 300nLmin1. Protein IDs were obtained by joined SEQUEST HT/Mascot search in Proteome Discoverer.
[(Fig._3)TD$FIG]
Fig. 3. Inﬂuence of gradient time (90min vs 120min) onto the number of identiﬁed proteins arising frommelanomaMM835 tissue lysates prepared by buffer exchange (1) or
dilution to 1M urea (2) prior to enzymatic digestion with trypsin (A) or trypsin/Lys C (B). Samples were analysed in duplicates. Peptides were separated on a 50 cm long
column (75mm2mm) at a ﬂow rate of 300nLmin1. Protein IDs were obtained by joined SEQUEST HT/Mascot search in Proteome Discoverer.
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respectively). There was no signiﬁcant difference in the number of
detected proteins for the two digestion protocols. In summary the
most efﬁcient, in terms of protein IDs, deep proteome approach
involved a buffer exchange step before enzymatic digestion with
trypsin and chromatographic separation in 120min gradient
generating a total number of 2520 protein and [86_TD$DIFF]11,606 peptide
identiﬁcations for one sample measured in duplicate.
3.5. Comparison of single- and two-dimension LC–MS/MS approaches
In the present study, ofﬂine fractionation was applied on
peptide level to resolve proteins, which are otherwise rarely
observed with the one-dimensional experimental setup. A
complex mixture of peptides produced by digestion was loaded
onto SCXmicrospin column. Peptideswere eluted from the column
with an increased salt gradient and each fractionwas desaltedwith
a C18 microspin column. The puriﬁed mixture of peptides was
concentrated on a trap column and separated using an analytical
column coupled to a mass spectrometer (Fig. 4).
Two sets of samples belonging to ‘high-immune’ and ‘pigmen-
tation’ subclasses identiﬁed in a genomic study [9] were compared
in one- and two-dimensional approaches. Each cohort contained
three tissue samples (MM687, MM787, MM813 belonging to
‘pigmentation’ and MM825, MM829, MM835 belonging to ‘high-
immune’ subclasses) separately prepared and analysed in tripli-
cates. With the one-dimensional approach, a total of 3888 and
3574 proteins belonging to 1955 and 1832 protein groups were
identiﬁed for ‘pigmentation’ and ‘high-immune’ subtypes, respec-
tively. The MudPIT approach allowed detection of 5950 proteins
(3191 protein groups) in ‘pigmentation’ and 5843 proteins (3129
protein groups) in the ‘high-immune’ set of samples. As the results
indicate, orthogonality of MudPIT technology allows for deeper
proteome analysis with about 36% increase in a number of
identiﬁed proteins (7282 proteins belonging to 3752 protein
groups found in the two sets of fractionated samples vs 4667
proteins belonging to 2313 protein groups found in the two sets of
unfractionated samples). The combination of Q-Exactive Plus
instrumentation with chromatographic separation performed at
constant column temperature (35 C) allowed for more proteins to
be identiﬁed in comparison with the pilot study conducted under
similar conditions on Q-Exactive by Welinder et al. [27]. Since the
MudPIT approach dramatically increases the time for analysis and
taking into account that only a part of all peptides is present in each
fraction, it seems reasonable to run MudPIT with reduced a
gradient, such as 90min.
4. Conclusions
The present study focuses on deﬁning methodology for
following large-scale analysis of more than 200 melanoma tissue
samples. The ﬁnal optimal workﬂow included complete removal of
urea from the tissue lysate and dissolving the mixture of proteins
in buffer compatible with both enzymatic digestion and MS
analysis. Since no added value was obtained with two-enzyme
digestion protocol, peptides were digested with trypsin alone.
Sample handling for one-enzyme digestion protocol was also less
elaborate. The number of identiﬁed proteins was increased by 36%
when a two-dimensional peptide separation approach (MudPIT)
was utilised. Twounintrusive internal standards, chicken lysozyme
and PRTC, were introduced to monitor the sample preparation
process, the chromatographic separation and the mass spectro-
metric measurements. With the [87_TD$DIFF]ﬁnalised workﬂow it is now
possible to [88_TD$DIFF]analyse a large number of samples in a controlled
manner with a high number of protein IDs within a single LC–MS
run. Protein expression data will be collected in a local melanoma
database and used to deepen knowledge about various disease
subtypes and drug resistance.
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